Biogen Inc.Biogen Inc. • April 30th, 2020 • Biological products, (no disgnostic substances) • New York
Biogen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman Sachs & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and each of the other Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the “Representatives”), the respective amounts set forth in Schedule I of $1,500,000,000 aggregate principal amount of the Company’s 2.250% Senior Notes due 2030 (the “2030 Notes”) and $1,500,000,000 aggregate principal amount of the Company’s 3.150% Senior Notes due 2050 (the “2050 Notes” and, together with the 2030 Notes, the “Securities”).
and U.S. Bank National Association, as Trustee Second Supplemental Indenture Dated as of April 30, 2020Supplemental Indenture • April 30th, 2020 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
SUPPLEMENTAL INDENTURE (this “Second Supplemental Indenture”), dated as of April 30, 2020, between BIOGEN INC., a Delaware corporation (the “Company”), and U.S. Bank National Association, a national association, as Trustee (the “Trustee”).
